A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

This breakthrough could significantly advance treatments aimed at neurodegenerative diseases by focusing on G4 regulation. Since G4s are also implicated in other diseases such as Alzheimer's ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...

BioVie (BIVI) announced that the upcoming PD-202 A Double-Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkinson’s Disease is now fully funded. Favorable ...

Parkinson's disease is a debilitating neurological ... appear years before an official diagnosis is made. This pioneering UK study delved into the neurodegenerative disorder within a diverse ...

Study of Bezisterim in Subjects with Early Parkinson’s Disease is now fully funded. Favorable capital market conditions last week enabled the company to raise over $15 million from secondary ...

And the festivities continue with the Autumn Fayre on Saturday, from 2pm to 4pm, at Halifax Elim Church, Hall Street. This ...

Walk for Parkinson’s event at Battersea Park in London on September 14.Attendees had the choice of either a 1.5-mile route or a six-mile walk, starting from the park's well-known Bandstand area and ...